Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter.

BACKGROUND The optimal upper limit of the normal range for prostate-specific antigen (PSA) is unknown. We investigated the prevalence of prostate cancer among men in the Prostate Cancer Prevention Trial who had a PSA level of 4.0 ng per milliliter or less. METHODS Of 18,882 men enrolled in the prevention trial, 9459 were randomly assigned to receive placebo and had an annual measurement of PSA and a digital rectal examination. Among these 9459 men, 2950 men never had a PSA level of more than 4.0 ng per milliliter or an abnormal digital rectal examination, had a final PSA determination, and underwent a prostate biopsy after being in the study for seven years. RESULTS Among the 2950 men (age range, 62 to 91 years), prostate cancer was diagnosed in 449 (15.2 percent); 67 of these 449 cancers (14.9 percent) had a Gleason score of 7 or higher. The prevalence of prostate cancer was 6.6 percent among men with a PSA level of up to 0.5 ng per milliliter, 10.1 percent among those with values of 0.6 to 1.0 ng per milliliter, 17.0 percent among those with values of 1.1 to 2.0 ng per milliliter, 23.9 percent among those with values of 2.1 to 3.0 ng per milliliter, and 26.9 percent among those with values of 3.1 to 4.0 ng per milliliter. The prevalence of high-grade cancers increased from 12.5 percent of cancers associated with a PSA level of 0.5 ng per milliliter or less to 25.0 percent of cancers associated with a PSA level of 3.1 to 4.0 ng per milliliter. CONCLUSIONS Biopsy-detected prostate cancer, including high-grade cancers, is not rare among men with PSA levels of 4.0 ng per milliliter or less--levels generally thought to be in the normal range.

[1]  G. Murphy,et al.  Purification of a human prostate specific antigen. , 1979, Investigative urology.

[2]  T. Ruebush,et al.  A double-blind study of trimethoprim-sulfamethoxazole prophylaxis in patients having transrectal needle biopsy of the prostate. , 1979, The Journal of urology.

[3]  G. Murphy,et al.  Quantitation of prostate-specific antigen in serum by a sensitive enzyme immunoassay. , 1980, Cancer research.

[4]  G. Murphy,et al.  Serum prostatic antigen measurement in localized prostatic cancer: correlation with clinical course. , 1982, The Journal of urology.

[5]  G. Murphy,et al.  Multiple marker evaluation in human prostate cancer with the use of tissue-specific antigens. , 1982, Journal of the National Cancer Institute.

[6]  R. Liedtke,et al.  Measurement of prostate-specific antigen by radioimmunoassay. , 1984, Clinical chemistry.

[7]  I. Thompson,et al.  Adenocarcinoma of the prostate: results of routine urological screening. , 1984, The Journal of urology.

[8]  F. Lee,et al.  Transrectal ultrasound in the diagnosis of prostate cancer: Location, echogenicity, histopathology, and staging , 1986, The Prostate.

[9]  L. Shaw,et al.  Evaluation of prostate-specific antigen and prostatic acid phosphatase as prostate cancer markers. , 1986, Urology.

[10]  P. Smith,et al.  Tumour markers in prostatic carcinoma. A comparison of prostate-specific antigen with acid phosphatase. , 1987, British journal of urology.

[11]  H. Ragde,et al.  Ultrasound-guided prostate biopsy. Biopty gun superior to aspiration. , 1988, Urology.

[12]  W. Cooner,et al.  Prostate cancer detection in a clinical urological practice by ultrasonography, digital rectal examination and prostate specific antigen. , 1990, The Journal of urology.

[13]  W. Catalona,et al.  Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. , 1991, The New England journal of medicine.

[14]  J. Richie,et al.  Selection of optimal prostate specific antigen cutoffs for early detection of prostate cancer: receiver operating characteristic curves. , 1994, The Journal of urology.

[15]  J. Oesterling,et al.  Age- and race-specific reference ranges for prostate-specific antigen from a large community-based study. , 1996, Urology.

[16]  R. Lamerz,et al.  Screening for prostatic carcinoma with prostate specific antigen. , 1997, Anticancer research.

[17]  A S Whittemore,et al.  Prostate cancer incidence and mortality in the United States and the United Kingdom. , 1998, Journal of the National Cancer Institute.

[18]  J. Hanley,et al.  Competing Risk Analysis of Men Aged 55 to 74 Years at Diagnosis Managed Conservatively for Clinically Localized Prostate Cancer , 1998 .

[19]  J. Melamed,et al.  Two consecutive sets of transrectal ultrasound guided sextant biopsies of the prostate for the detection of prostate cancer. , 1998, The Journal of urology.

[20]  O. Brawley,et al.  The epidemiology of prostate cancer part I: descriptive epidemiology. , 1998, Seminars in urologic oncology.

[21]  F. Labrie,et al.  Screening decreases prostate cancer death: First analysis of the 1988 Quebec Prospective Randomized Controlled Trial , 1999, The Prostate.

[22]  J. Gohagan,et al.  The Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial of the National Cancer Institute: history, organization, and status. , 2000, Controlled clinical trials.

[23]  D. Gunnell,et al.  Comparison of trends in prostate-cancer mortality in England and Wales and the USA , 2000, The Lancet.

[24]  M S Pepe,et al.  Phases of biomarker development for early detection of cancer. , 2001, Journal of the National Cancer Institute.

[25]  J. Crowley,et al.  Biomarker-based methods for determining noncompliance in a prevention trial. , 2002, Controlled clinical trials.

[26]  P. Humphrey,et al.  Prostate-specific antigen cutoff of 2.6 ng/mL for prostate cancer screening is associated with favorable pathologic tumor features. , 2002, Urology.

[27]  Michael M Lieber,et al.  Journal Review , 2003, International Society of Hair Restoration Surgery.

[28]  William J Catalona,et al.  Effect of verification bias on screening for prostate cancer by measurement of prostate-specific antigen. , 2003, The New England journal of medicine.

[29]  I. Thompson,et al.  The Prostate Cancer Prevention Trial: design, status, and promise , 2003, World Journal of Urology.